Connection Between Epigenome, Selective Mutability, Evolution, and Human Disease
Li, Harris et al., PLoS Genetics
Researchers at the Baylor College of Medicine and elsewhere propose a "connection between the epigenome, selective mutability, evolution, and human disease" based on the findings of their study on associations of structural mutability with germline DNA methylation and with non-allelic homologous recombination mediated by low-copy repeats. "Combined evidence from four human sperm methylome maps, human genome evolution, structural polymorphisms in the human population, and previous genomic and disease studies consistently points to a strong association of germline hypomethylation and genomic instability," the Baylor-led team writes.
Signal Genetics Debuts Gene Expression-Based Prognostic for Multiple Myeloma
Signal Genetics last weekend debuted its MyPRS multiple myeloma prognostic assay.
The whole-genome test, which stands for Myeloma Prognostic Risk Signature, interrogates 70 genes with an internally developed algorithm to help predict a patient’s outcome.
Signal Genetics, which is based in New York City, will perform the test at its CLIA lab in Little Rock, Ark., and will offer it through "select" specialty commercial labs.
The debut comes nearly three months after Signal Genetics said it would use the MyPRS test in a multiple myeloma research program conducted by drug maker Array BioPharma.
Got a tip? Click my byline above to send it along or submit it as a comment below. Follow my headlines on Twitter or subscribe to my RSS feed. Learn more about me or become a source via Linkedin, where all conversations are confidential.